Publications Scientifiques

• Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

  J Clin Invest. 2020
  Télécharger

• SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid‐derived suppressor cells

  Am J Transplant. 2019
  Télécharger

• Early signs of activity of Tedopi® (OSE2101), a multiple neoepitope vaccine, in a phase 3 trial in advanced lung cancer patients after failure to previous immune checkpoint inhibitors (ATALANTE-1)

  Santiago Viteri et al., AACR 2019
  Télécharger

• Full antagonist of the IL-7 receptor suppresses chronic inflammation in non-human primate models by controlling antigen-specific memory T cells

  Cess Stress, Micro Review, 10 Decembre 2018
  Télécharger

• Vaccines as an Integral Component of Cancer Immunotherapy

  JAMA, November 8, 2018
  Télécharger

• T-cytotoxic specific immunotherapy in NSCLC with brain metastases

  J. Nemunaitis et al., WCLC, 2015
  Télécharger

• Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection

  Ville et al, J Am Soc Nephrol 2016
  Télécharger

• Inducing CTLA-4-Dependent Immune Regulation by Selective CD28 Blockade Promotes Regulatory T Cells in Organ Transplantation

  Poirier et al, Science Transl Med 2010
  Télécharger

• CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates

  Watkins et al, JCI 2018
  Télécharger

• IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation

  nature communications, 26 October 2018
  Télécharger

• Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis

  Vierboom et al., Clin Exp Immunol. 2016
  Télécharger

• Efficacy, safety and predictive biomarkers results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2/3L NSCLC (POLAR) 

  J Clin Oncol 2015; 33 (suppl; abstr 8010)
  Télécharger

• Optimizing PD-L1 as biomarker of response with pembrolizumab as first-line therapy for PD-L1 positive metastatic non-small cell lung cancer

  J Clin Oncol. 33 (2015)
  Télécharger

• Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)

  J Clin Oncol 33 (2015)
  Télécharger

• T-cytotoxic specific immunotherapy in NSCLC with brain metastases

  16th world conference on lung cancer (September 2015)
  Télécharger

• Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial 

  Lancet Oncology (2013)
  Télécharger

• Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

  Cell (2016)
  Télécharger

• Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

  Cancer Biol Med. (2015)
  Télécharger

• Selective SIRPa blockade potentiates dendritic cell antigen cross-presentation and triggers memory T-cell antitumor responses

  Poster AACR (2018)
  Télécharger

• SIRPa inhibition monotherapy leads to dramatic change in solid tumor microenvironment and prevents metastasis development

  Poster AACR (2018)
  Télécharger

• Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

  Genome Research (2014)
  Télécharger

• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study

  Journal of Clinical Oncology (2012)
  Télécharger

• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

  New England Journal of Medicine (2015)
  Télécharger

• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  Science (2016)
  Télécharger

• Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors

  Strauss J et al., Expert Opin Biol Ther (2016)
  Télécharger

• Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

  Annals of Oncology (2016)
  Télécharger

• The Dual Role of Myeloid-Derived Suppressor Cells in Liver Pathologies

  J Liver Clin Res 1(1): 1001 (2014)
  Télécharger

• Increase in CD14+HLA-DR2/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

  Cancer Immunol Immunother 62:1421–1430 (2013)
  Télécharger

• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

  Lancet Oncology (2012)
  Télécharger

• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  Nature vol 515 (Nov 2014)
  Télécharger

• Selective targeting of SIRP-alpha induces potent memory anti-tumor immune responses without presenting haematological toxicity

  Poster AACR (2017)
  Télécharger

• Dual targeting of adaptive and innate checkpoints induce potent memory anti-tumor response

  Poster EACR (2016)
  Télécharger

• Control of immune tolerance by the SIRPα – CD47 pathway and Myeloid-Derived Suppressor Cells

  Poirier N. et al. - Poster EACR (2016)
  Télécharger

• Selective targeting of the SIRPα immune checkpoint, but not CD47, controls the polarization of macrophages

  Poster Philadelphie & EACR (2016)
  Télécharger

• Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor

  Kei Suzuki, Kyuichi Kadota, Camelia S. Sima et al.; Journal of Clinical Oncology (Feb. 2013)
  Télécharger

• The role of IL-7 in Immunity and Cancer

  Jack Lin et al., Anticancer Research 37: 963-968 (2017)
  Télécharger

• The present and future of inflammatory bowel disease treatments

  Gastroenter. Hepatol 12, 438-441 (2016)
  Télécharger

• Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J. Immunol.

  J. Immunol. 171, 1556–1563 (2003)
  Télécharger

• The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells.

  Immunity 37, 674–684 (2012)
  Télécharger

• IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa

  Poster FOCIS (2017)
  Télécharger

• Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNFα therapy in patients with inflammatory bowel disease

  Poster AAI (2018)
  Télécharger

• IL-7 receptor blockade prevents intestinal human T cells infiltration by modulation of alpha4-beta7 integrin expression

  Abstract FOCIS (2016)
  Télécharger

• Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses

  Zaitsu M. et al.; Journal of Clinical Investigation (2017)
  Télécharger

• Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection

  Journal of the American Society of Nephrology (2016)
  Télécharger

• First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28

  Poirier N. et al.; Journal of Immunology (Nov. 2016)
  Télécharger

• CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity

  Dillinger B. et al.; Frontiers in Immunology (2017)
  Télécharger